Kevin Fu, MD
Nephrology · Tulsa, OKNPI 1376938167
Payments from drug & device makers
Across 509 payments — averaging $27.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Amgen$2K
- Daiichi Sankyo Inc.$966
- Bayer$954
- Baxter Healthcare$873
- OPKO Pharmaceuticals, LLC$650
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$5004%
- Food & beverage$13,16994%
- Education$3432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 78 | $3,165 |
| Amgen(2 entities) | 85 | $2,249 |
| Daiichi Sankyo Inc. | 38 | $966 |
| Bayer | 51 | $954 |
| Baxter Healthcare | 9 | $873 |
| OPKO Pharmaceuticals, LLC | 40 | $650 |
| Aurinia Pharma U.S., Inc. | 24 | $569 |
| Otsuka America Pharmaceutical, Inc. | 24 | $507 |
| Novartis | 21 | $464 |
| Vifor Pharma, Inc. | 20 | $372 |
| Boehringer Ingelheim | 14 | $277 |
| Travere Therapeutics, Inc. | 10 | $267 |
| Novo Nordisk | 12 | $254 |
| Johnson & Johnson | 2 | $248 |
| GSK | 15 | $238 |
| Calliditas Therapeutics US Inc. | 11 | $236 |
| Bard Peripheral Vascular, Inc. | 3 | $211 |
| Vantive US Healthcare LLC | 3 | $211 |
| Mallinckrodt Hospital Products Inc. | 5 | $198 |
| Pharmacosmos Therapeutics Inc. | 10 | $179 |
| Cormedix Inc. | 4 | $179 |
| BD | 1 | $142 |
| Akebia Therapeutics Inc | 6 | $110 |
| ANI Pharmaceuticals, Inc. | 5 | $95 |
| Ardelyx, Inc. | 5 | $93 |
| Veloxis Pharmaceuticals, Inc. | 3 | $77 |
| Scpharmaceuticals Inc. | 2 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Nuwellis, Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Corium, LLC | 1 | $24 |
| Abbott | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Nxstage Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,393
- LOKELMA$389
- Parsabiv$376
- Tavneos$338
- XARELTO$248
- KRYSTEXXA$247
- Renal - Acute$223
- Renal - PrisMax System$210
- INJECTAFER$138
- DefenCath$127
- Sensipar$127
- Renal - PD$112
- LUPKYNIS$106
- Gambro - Accute$101
How this compares
$14,012 in reported general payments places this provider in the 90th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LokelmaSodium Zirconium Cyclosilicate | 17 | $14,881 |
| Sevelamer Carbonate | 17 | $5,019 |
| Torsemide | 59 | $1,619 |
| Doxazosin Mesylate | 61 | $1,512 |
| Amlodipine Besylate | 104 | $1,357 |
| Furosemide | 128 | $1,083 |
| Potassium Chloride | 32 | $961 |
| Carvedilol | 42 | $559 |
| Bumetanide | 12 | $419 |
| Losartan Potassium | 33 | $385 |
| Tamsulosin Hcl | 24 | $375 |
| Metoprolol Tartrate | 23 | $170 |
| Allopurinol | 14 | $152 |
| Hydrochlorothiazide | 21 | $111 |
| Hydralazine Hcl | 11 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma | $3,165 | $14,88117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Tulsa
- Sunil AgrawalTulsa$40K
- Pranay KathuriaTulsa$21K
- Diptesh GuptaTulsa$13K
- Janet RussellTulsa$12K
- Bobby MuthalalyTulsa$12K
- Narottam RegmiTulsa$12K
- Alpana PasrichaTulsa$9K
- Reza AzadiTulsa$9K
- Christine WilsonTulsa$8K
- Kusum BhandariTulsa$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.